Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply clinical-grade MagSense® nanoparticle formulations for the Company’s planned HER2 breast cancer human clinical studies.
View the ASX announcement, “Imagion Biosystems Secures Nanoparticle Manufacturer.”
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce